Formalin-inactivated bovine RSV vaccine influences antibody levels in bronchoalveolar lavage fluid and disease outcome in experimentally infected calves.
Respiratory syncytial virus (RSV) causes severe respiratory disease in calves and human infants. In response to outbreaks, formalin inactivated (FI)-RSV vaccines were developed and found to exacerbate disease following a live RSV infection. We have reproduced vaccination induced disease enhancement in calves and screened various antibody isotypes in bronchoalveolar lavage fluid (BALF) from two studies: one with disease enhancement and another where moderate protection resulted from FI-bovine RSV (BRSV) vaccination. Semi-protected vaccinated calves produced BRSV-specific BALF IgG1, but not IgA and IgG2 prior to infection; whereas, calves with enhanced disease failed to develop BRSV-specific IgG1 in BALF. Ultimately, the formulation and delivery of RSV vaccines influences protective antibody levels in respiratory secretions.